natgillin/translations-raw huggingface dataset:
I et omhyggeligt QTc-studie hos raske, frivillige mænd havde enkeltdoser på Entresto 194 mg sacubitril/206 mg valsartan og 583 mg sacubitril/617 mg valsartan ingen virkning på hjertets repolarisation. 
In a thorough QTc clinical study in healthy male subjects, single doses of Entresto 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarisation.
Entresto er indiceret til behandling af voksne patienter med symptomatisk kronisk hjertesvigt med nedsat uddrivningsfraktion (se pkt. 
Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).
Det anbefales at monitorere serumkalium, hvis Entresto administreres sammen med disse stoffer (se pkt. 
Monitoring of serum potassium is recommended if Entresto is co-administered with these agents (see section 4.4).
Entrestos komplementære kardiovaskulære fordele hos patienter med hjertesvigt forklares med, at peptider, som nedbrydes af neprilysin, som fx natriuretiske peptider (NP), øges ved hjælp af LBQ657 samtidigt med, at de virkninger, som forårsages af angiotensin II, hæmmes ved hjælp af valsartan. 
The complementary cardiovascular benefits of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan.
I den dobbeltblinde periode af PARADIGM-HF-studiet forekom afbrydelse af behandlingen hos 450 patienter behandlet med Entresto (10,7 %) og 516 patienter behandlet med enalapril (12,2 %). 
Discontinuation of therapy due to an adverse reaction in the double-blind period of the PARADIGM-HF study occurred in 450 Entresto-treated patients (10.7%) and 516 enalapril-treated patients (12.2%).
Hvis du har glemt at tage Entresto Det anbefales, at tage medicinen på samme tidspunkt hver dag. 
It is advisable to take your medicine at the same time each day.
Antal risikopatienter Entresto 
No. at risk Entresto
I PARADIGM-HF forekom hyperkaliæmi og serumkaliumkoncentrationer på >5,4 mmol/l hos henholdsvis 11,6 % og 19,7 % af patienter behandlet med Entresto og henholdsvis 14,0 % og 21,1 % af patienter behandlet med enalapril. 
In PARADIGM-HF, hyperkalaemia and serum potassium concentrations >5.4 mmol/l were reported in 11.6% and 19.7% of Entresto-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.
De mest almindeligt rapporterede bivirkninger ved behandling med Entresto var hypotension, hyperkaliæmi og nedsat nyrefunktion (se pkt. 
The most commonly reported adverse reactions during treatment with Entresto were hypotension, hyperkalaemia and renal impairment (see section 4.4).
***En-sidet p-værdi 
***One-sided p-value ♯ Full analysis set
Entresto skal derfor anvendes med forsigtighed hos disse patienter og den anbefalede startdosis er 24 mg/26 mg to gange daglig (se pkt. 
Entresto should be used with caution in these patients and the recommended starting dose is 24 mg/26 mg twice daily (see sections 4.4 and 5.2).
I dette studie var CSF Aβ clearence hos cynomolgus aber reduceret, idet CSF Aβ1-40, 1-42 og 138 niveauer øgedes. 
In this study CSF Aβ clearance in cynomolgus monkeys was reduced, increasing CSF Aβ1-40, 1-42 and 1-38 levels; there was no corresponding increase in Aβ levels in the brain.
Entresto er kontraindiceret hos patienter, som tidligere har oplevet angioødem relateret til ACE-hæmmere, til behandling med ARB eller med hereditær eller idiopatisk angioødem (se pkt. 
Entresto is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or with hereditary or idiopathic angioedema (see section 4.3).
Dyrestuder med Entresto har vist reproduktionstoksicitet (se pkt. 
Animal studies with Entresto have shown reproductive toxicity (see section 5.3).
Interaktion mellem Entresto og lithium er ikke undersøgt, denne kombination kan derfor ikke anbefales. 
Interactions between Entresto and lithium have not been investigated.
Patienterne skulle afbryde deres eksisterende ACE-hæmmer- eller ARB-behandling og indgå i en sekventiel enkeltblindet run-in periode, i hvilken de blev behandlet med 10 mg enalapril 2 gange daglig efterfulgt af enkeltblindet behandling med Entresto 100 mg 2 gange daglig stigende til 200 mg 2 gange daglig (se pkt. 
Patients were required to discontinue their existing ACE inhibitor or ARB therapy and enter a sequential single-blind run-in period during which they received treatment with enalapril 10 mg twice daily, followed by single-blind treatment with Entresto 100 mg twice daily, increasing to 200 mg twice daily (see section 4.8 for discontinuations during this period).
Kombination af Entresto med aliskiren er muligvis forbundet med en højere hyppighed af bivirkniner som fx hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) (se pkt. 
Combination of Entresto with aliskiren is potentially associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) (see sections 4.3 and 4.4).
BNP er ikke egnet som biomarkør for hjertesvigt hos patienter i behandling med Entresto, da BNP er et neprilysinsubstrat (se pkt. 
BNP is not a suitable biomarker of heart failure in patients treated with Entresto because BNP is a neprilysin substrate (see section 4.4).
Der er nogenlunde lineær farmakokinetik af sacubitril, LBQ657 og valsartan i et dosisinterval af Entresto mellem 24 mg sacubitril/26 mg valsartan og 97 mg sacubitril/103 mg valsartan. 
The pharmacokinetics of sacubitril, LBQ657 and valsartan were approximately linear over an Entresto dose range of 24 mg sacubitril/26 mg valsartan to 97 mg sacubitril/103 mg valsartan.
BNP er ikke egnet som markør for hjertesvigt hos patienter behandlet med Entresto, da dette er et neprilysinsubstrat (se pkt. 
BNP is not a suitable biomarker of heart failure in patients treated with Entresto because it is a neprilysin substrate (see section 5.1).
Hvis du stopper med at tage Entresto, skal du vente i 36 timer efter at have taget din sidste dosis Entresto, før du må begynde at tage en ACE-hæmmer. 
If you stop taking Entresto, wait 36 hours after taking your last dose of Entresto before starting an ACE inhibitor.
I PARADIGM-HF forekom nedsat nyrefunktion hos 10,1 % af patienter behandlet med Entresto og hos 11,5 % af patienter behandlet med enalapril. 
In PARADIGM-HF, renal impairment was reported in 10.1% of Entresto-treated patients and 11.5% of enalapril-treated patients.
Entresto udøver virkningsmekanismen af en angiotensinreceptor-neprilysin-hæmmer idet LBQ657, som er den aktive metabolit af prodruget sacubitril, hæmmer neprilysin (neutral endopeptidase; NEP) samtidig med, at valsartan blokerer angiotensin II type-1 (AT1) receptoren. 
Entresto exhibits the mechanism of action of an angiotensin receptor neprilysin inhibitor by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan.
Virkningen af Entresto på human fertilitet er ikke undersøgt. 
There are no available data on the effect of Entresto on human fertility.
14 filmovertrukne tabletter 20 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 168 filmovertrukne tabletter 196 filmovertrukne tabletter 
14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 168 film-coated tablets 196 film-coated tablets
Hvis noget af ovenstående passer på dig, skal du tale med din læge, apotekspersonalet eller sygeplejersken, før du tager Entresto. 
If any of the above applies to you, tell your doctor, pharmacist or nurse before you take Entresto.
Entresto er kontraindiceret hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (Child-Pugh klasse C) (se pkt. 
Entresto is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).
Tabletdimensioner er ca. 13,1 mm x 5,2 mm. Entresto 49 mg/51 mg filmovertrukne tabletter 
Approximate tablet dimensions 13.1 mm x 5.2 mm. Entresto 49 mg/51 mg film-coated tablets
14 filmovertrukne tabletter 20 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 196 filmovertrukne tabletter 
14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 196 film-coated tablets
Entresto 97 mg/103 mg filmovertrukne tabletter 
Entresto 97 mg/103 mg film-coated tablets
Hvis noget af ovenstående passer på dig, skal du tale med din læge eller apotekspersonalet før du tager Entresto. 
If any of the above applies to you, tell your doctor or pharmacist before you take Entresto.
Hvis du har taget en ACE-hæmmer, skal du vente i 36 timer efter at have taget den sidste dosis, før du begynder at tage Entresto (se ”Brug af anden medicin sammen med Entresto”). 
If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).
Entresto 24 mg/26 mg filmovertrukne tabletter 
Entresto 24 mg/26 mg film-coated tablets
Entresto 49 mg/51 mg filmovertrukne tabletter 
Entresto 49 mg/51 mg film-coated tablets
Pakningsstørrelser: 14, 20, 28, 56, 168 eller 196 filmovertrukne tabletter og multipakninger indeholdende 168 (3x56) eller 196 (7x28) filmovertrukne tabletter. 
Pack sizes: 14, 20, 28, 56, 168 or 196 film-coated tablets and multipacks containing 168 (3x56) or 196 (7x28) film-coated tablets.
Tabletdimensioner er ca. 13,1 mm x 5,2 mm. Entresto 97 mg/103 mg filmovertrukne tabletter 
Approximate tablet dimensions 13.1 mm x 5.2 mm. Entresto 97 mg/103 mg film-coated tablets
Med baggrund i en lille forekomst af føtal hydrocephali relateret til maternelle toksiske doser, som sås hos kaniner ved en Entrestodosis ≥4,9 mg sacubitril/5,1 mg valsartan/kg/dag, er 
It is teratogenic based on a low incidence of foetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an Entresto dose of ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day.
Entresto 24 mg/26 mg filmovertrukne tabletter Entresto 49 mg/51 mg filmovertrukne tabletter Entresto 97 mg/103 mg filmovertrukne tabletter 
Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets
Entresto 49 mg/51 mg filmovertrukne tabletter er svagt gule ovale tabletter med ”NVR” på den ene side og ”L1” på den anden side. 
Entresto 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side.
Kombination af Entresto med direkte reninhæmmere som fx aliskiren frarådes (se pkt. 
The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.4).
Hvis du har taget en ACEhæmmer, skal du vente i 36 timer efter at have taget den sidste dosis ACE-hæmmer, før du kan starte med at tage Entresto (se ”Tag ikke Entresto”). 
If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Entresto (see “Do not take Entresto”).
Behandling med Entresto under organdannelsen resulterede i øget embryoføtal dødelighed hos rotter ved doser ≥49 mg sacubitril/51 mg valsartan/kg/dag (≤0,72 gange den maksimalt anbefalede dosis til mennesker [MRHD] vurderet ud fra AUC) og kaniner ved doser ≥4,9 mg sacubitril/5,1 mg valsartan/kg/dag (henholdsvis 2 gange og 0,03 gange MHRD vurderet ud fra AUC for valsartan og LBQ657). 
≥49 mg sacubitril/51 mg valsartan/kg/day (≤0.72-fold the maximum recommended human dose [MRHD] on the basis of AUC) and rabbits at doses ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively).
Pakningsstørrelser: 14, 20, 28, 56 eller 196 filmovertrukne tabletter og multipakninger indeholdende 196 (7x28) filmovertrukne tabletter. 
Pack sizes: 14, 20, 28, 56 or 196 film-coated tablets and multipacks containing 196 (7x28) film-coated tablets.
4.8), især hos patienter ≥65 år, patienter med nyresygdom og patienter med lavt SBT (<112 mmHg.). 
Cases of symptomatic hypotension have been reported in patients treated with Entresto during clinical studies (see section 4.8), especially in patients ≥65 years old, patients with renal disease and patients with low SBP (<112 mmHg).
Entresto må ikke påbegyndes før 36 timer efter indtagelse af den sidste dosis ACE-hæmmer. 
Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Entresto 24 mg/26 mg filmovertrukne tabletter Entresto 49 mg/51 mg filmovertrukne tabletter Entresto 97 mg/103 mg filmovertrukne tabletter sacubitril/valsartan 
Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Ydermere var der ingen tegn på forekomst af amyloid plaques i hjernen hos cynomolgus aber, der blev behandlet med Entresto 146 mg sacubitril/154 mg valsartan/kg/dag i 39 uger i et toksikologisk studie. 
Additionally, in a toxicology study in cynomolgus monkeys treated with Entresto at 146 mg sacubitril/154 mg valsartan/kg/day for 39 weeks, there was no evidence for the presence of amyloid plaques in the brain.
Hvis behandling med Entresto afbrydes, må behandling med ACEhæmmer ikke påbegyndes før 36 timer efter sidste dosis Entresto (se pkt. 
If treatment with Entresto is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Entresto (see sections 4.2, 4.3 and 4.5).
• Entresto indeholder valsartan og må derfor ikke gives sammen med et andet produkt indeholdende en ARB. 
• Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Sådan skal du tage Entresto 
How to store Entresto
Hyponatriæmi og/eller hypovolæmi bør korrigeres før behandling med Entresto påbegyndes. 
Sodium and/or volume depletion should be corrected before starting treatment with Entresto, however, such corrective action must be carefully weighed against the risk of volume overload.
Entresto 24 mg/26 mg filmovertrukne tabletter er violet-hvide ovale tabletter med ”NVR” på den ene side og ”LZ” på den anden side. 
What Entresto looks like and contents of the pack Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Anvendelse af Entresto sammen med produkter indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller hos patienter med nedsat nyrefunktion (eGFR <60 ml/min/1,73 m2) (se pkt. 
The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Entresto må ikke indgives før 36 timer efter behandling med ACE-hæmmer er afbrudt. 
Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
• På grund af en øget risiko for angioødem er en kombination af Entresto og en ACE-hæmmer kontraindiceret (se pkt. 
• The combination of Entresto with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Entresto er ikke undersøgt hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (se pkt. 
Entresto has not been studied in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (see sections 4.3 and 4.4).
Entresto 49 mg/51 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171) 
Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Entresto 97 mg/103 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171) 
Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Det er derfor muligt, at anvendelse af Entresto sammen med hæmmere af OATP1B1, OATP1B3 og OAT3 (fx rifampicin, ciclosporin), OAT1 (fx tenofovir, cidofovir) eller MRP2 (fx ritonavir) kan øge den systemiske eksponering af LBQ657 eller valsartan. 
Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Hvis du har taget for meget Entresto 
If you take more Entresto than you should
Entresto 24 mg/26 mg tabletter sacubitril/valsartan 
Entresto 24 mg/26 mg tablets sacubitril/valsartan
Entresto 97 mg/103 mg tabletter sacubitril/valsartan 
Entresto 97 mg/103 mg tablets sacubitril/valsartan
Entresto 24 mg/26 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171) 
Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
• Det frarådes at give Entresto sammen med en direkte reninhæmmer som fx aliskiren (se pkt. 
• The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Behandling med ACE-hæmmer må ikke påbegyndes før 36 timer efter den sidste dosis Entresto (se pkt. 
ACE inhibitor therapy must not be started until 36 hours after the last dose of Entresto (see sections 4.2 and 4.3).
En let øgning i to føtale, skeletale variationer (misdannet sternebra, tvedelt knogledannelse af sternebra) blev observeret hos kaniner ved en dosis af Entresto på 4,9 mg sacubitril/5,1 mg valsartan/kg/dag. 
A slight increase in two foetal skeletal variations (misshapen sternebra, sternebra bipartite ossification) was observed in rabbits at an Entresto dose of
Entresto 49 mg/51 mg tabletter sacubitril/valsartan 
Entresto 49 mg/51 mg tablets sacubitril/valsartan
Entresto 97 mg/103 mg filmovertrukne tabletter er lyserøde ovale tabletter med ”NVR” på den ene side og ”L11” på den anden side. 
Approximate tablet dimensions 13.1 mm x 5.2 mm Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Entresto 24 mg/26 mg filmovertrukne tabletter sacubitril/valsartan 
Entresto 24 mg/26 mg film-coated tablets sacubitril/valsartan
Entresto 97 mg/103 mg filmovertrukne tabletter sacubitril/valsartan 
Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Entresto 49 mg/51 mg filmovertrukne tabletter sacubitril/valsartan 
Entresto 49 mg/51 mg film-coated tablets sacubitril/valsartan
Da der er meget begrænset klinisk erfaring hos patienter med svært nedsat nyrefunktion (eGFR <30 ml/min/1,73 m2) (se pkt. 
As there is very limited clinical experience in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) (see section 5.1) Entresto should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.
• Kendt angioødem i anamnesen i forbindelse med tidligere behandling med ACE-hæmmer eller 
• Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
Fuldt analysesæt 
Tablet core
Dette vil sædvanligvis bringe mængden af calcium i blodet ned på et normalt niveau inden for en uge. 
This will normally bring the blood calcium level down to normal levels within a week.
Patienterne bør desuden tage D-vitamin- og calciumtilskud. 
Patients should also take vitamin D and calcium supplements.
Dette reducerer knogletabet. 
This reduces bone loss.
Den fuldstændige EPAR for Ibandronsyre Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR for Ibandronic acid Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Ibandronsyre Accord den 19. november 2012. 
The European Commission granted a marketing authorisation valid throughout the European Union for Ibandronic acid Accord on 19 November 2012.
Til forebyggelse af knoglerelaterede hændelser eller behandling af hypercalcæmi hos kræftpatienter bør behandling med dette lægemiddel kun indledes af en læge med erfaring i kræftbehandling. 
For the prevention of skeletal events or the treatment of hypercalcaemia in cancer patients, treatment with this medicine should only be started by a doctor who has experience in the treatment of cancer.
Der er allerede gennemført undersøgelser af fordelene og risiciene ved det aktive stof i de godkendte anvendelser med referencelægemidlerne, Bondronat og Bonviva, og det er ikke nødvendigt at gentage disse for Ibandronsyre Accord. 
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicines, Bondronat and Bonviva, and do not need to be repeated for Ibandronic acid Accord.
Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav er blevet påvist, at Ibandronsyre Accord er sammenlignelig med Bondronat og Bonviva. 
The European Medicines Agency concluded that, in accordance with EU requirements, Ibandronic acid Accord has been shown to be comparable to Bondronat and Bonviva.
• forebyggelse af "knoglerelaterede hændelser" (knoglebrud eller knoglekomplikationer, der kræver behandling) hos patienter med brystkræft og knoglemetastaser (kræft, der har spredt sig til knoglerne) 
• prevent ‘skeletal events' (fractures or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone);
Som for alle lægemidler fremlagde virksomheden undersøgelser af kvaliteten af Ibandronsyre Accord. 
As for every medicine, the company provided studies on the quality of Ibandronic acid Accord.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Ibandronsyre Accord. 
This is a summary of the European public assessment report (EPAR) for Ibandronic acid Accord.
• behandling af hypercalcæmi (øget mængde kalcium i blodet), der skyldes svulster. 
• treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.
Agenturet anbefalede, at Ibandronsyre Accord godkendes til anvendelse i EU. 
The Agency recommended that Ibandronic acid Accord be approved for use in the EU.
Der var ikke behov for "bioækvivalente" undersøgelser af, om Ibandronsyre Accord absorberes på samme måde som referencelægemidlerne for at producere samme niveau af det aktive stof i blodet. 
There was no need for ‘bioequivalence' studies to investigate whether Ibandronic acid Accord is absorbed similarly to the reference medicines to produce the same level of the active substance in the blood.
Dette skyldes, at Ibandronsyre Accord gives ved infusion eller injektion i en vene, så det aktive stof ledes direkte ind i blodbanen. 
This is because Ibandronic acid Accord is given by infusion or injection into a vein, so the active substance is delivered straight into the bloodstream.
Patienter med moderate eller svære nyreproblemer skal have infusionerne med Ibandronsyre Accord i en lavere dosis i løbet af en time. 
Patients with moderate or severe kidney problems should receive Ibandronic acid Accord infusions at a lower dose over an hour.
Reduktionen af knogletabet bidrager til at mindske sandsynligheden for knoglebrud hos kræftpatienter med knoglemetastaser og hos kvinder med osteoporose. 
The reduction of bone loss helps to make bones less likely to break in cancer patients with bone metastases and in women with osteoporosis.
Patienter med svulster kan have en forhøjet mængde calcium i blodet, der er afgivet fra knoglerne. 
Patients with tumours can have high levels of calcium in their blood, released from the bones.
Ved at forebygge nedbrydning af knoglerne medvirker Ibandronsyre Accord også til at mindske den mængde calcium, der afgives til blodet. 
By preventing the breakdown of bones, Ibandronic acid Accord also helps to reduce the amount of calcium released into the blood.